LON:AZN AstraZeneca (AZN) Share Price, News & Analysis £107.17 +108.82 (+1.03%) As of 05/2/2025 12:31 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityBuy This Stock About AstraZeneca Stock (LON:AZN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AstraZeneca alerts:Sign Up Key Stats Today's Range£105.99▼£107.9250-Day Range 9,669.50▼£120.7252-Week Range 9,573.51▼£133.88Volume2.19 million shsAverage Volume17.71 million shsMarket Capitalization£206.19 billionP/E Ratio29.38Dividend Yield2.18%Price TargetGBX 6,303.50Consensus RatingModerate Buy Company OverviewAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.Read More… AstraZeneca Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreAZN MarketRank™: AstraZeneca scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingModerate Buy Consensus RatingAstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAstraZeneca has only been the subject of 3 research reports in the past 90 days.Read more about AstraZeneca's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of AstraZeneca is 29.38, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.98.Price to Earnings Ratio vs. SectorThe P/E ratio of AstraZeneca is 29.38, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.81.Price to Earnings Growth RatioAstraZeneca has a PEG Ratio of 0.86. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAstraZeneca has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AZN. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldAstraZeneca pays a meaningful dividend of 1.23%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAstraZeneca does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of AstraZeneca is 64.14%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about AstraZeneca's dividend. Sustainability and ESG4.0 / 5Environmental Score-2.35 Short InterestThere is no current short interest data available for AZN. News and Social Media2.4 / 5News Sentiment0.28 News SentimentAstraZeneca has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for AstraZeneca this week, compared to 3 articles on an average week.Search InterestOnly 17 people have searched for AZN on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.MarketBeat Follows3 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AstraZeneca insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.04% of the stock of AstraZeneca is held by insiders.Percentage Held by Institutions51.03% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AstraZeneca's insider trading history. Receive AZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. Email Address AZN Stock News HeadlinesAstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled AsthmaMay 2 at 2:45 PM | finance.yahoo.comAstraZeneca’s Breztri Therapy Meets Primary Goals In Late-Stage Trials To Treat Asthma: Retail’s PositiveMay 2 at 9:45 AM | msn.comTrump Makes Major Crypto AnnouncementTrump's Pro-Crypto Agenda Finally Sparks Market Recovery With Bitcoin surging past $90,000 and altcoins heating up, I'm seeing all the signs of a major market shift For a limited time, I'm revealing the name and complete analysis behind my top Trump-era crypto pick. May 4, 2025 | Crypto 101 Media (Ad)AstraZeneca (LSE:AZN) Reports Higher Earnings, Dividend Increase, and Clinical Trial DiscontinuationApril 29, 2025 | uk.finance.yahoo.comFTSE 100 Live: Stocks start in stalemate as AstraZeneca and BP disappoint, Entain impressesApril 29, 2025 | uk.investing.comAstraZeneca shares fall as revenue miss tempers strong Q1 earningsApril 29, 2025 | za.investing.comFTSE today: stocks flat as HSBC, BP, AstraZeneca post resultsApril 29, 2025 | investing.comAstraZeneca warns of potential additional tax penalties in ChinaApril 29, 2025 | msn.comSee More Headlines AZN Stock Analysis - Frequently Asked Questions How have AZN shares performed this year? AstraZeneca's stock was trading at £104.68 at the beginning of 2025. Since then, AZN stock has increased by 2.4% and is now trading at £107.17. View the best growth stocks for 2025 here. How do I buy shares of AstraZeneca? Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of AstraZeneca own? Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Intel (INTC), Advanced Micro Devices (AMD) and Johnson & Johnson (JNJ). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryPharmaceutical Products Current SymbolLON:AZN CIKN/A Webwww.astrazeneca.com Phone+44-20-73045000FaxN/AEmployees83,500Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 6,303.50 High Stock Price Target£140 Low Stock Price TargetGBX 74 Potential Upside/Downside-41.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 364.83 Trailing P/E Ratio29.38 Forward P/E Ratio14.69 P/E Growth0.86Net Income£8.71 billion Net Margins13.01% Pretax MarginN/A Return on Equity17.76% Return on Assets7.68% Debt Debt-to-Equity Ratio73.83 Current Ratio0.93 Quick Ratio0.59 Sales & Book Value Annual Sales£66.95 billion Price / Sales3.08 Cash FlowGBX 275.56 per share Price / Cash Flow38.89 Book ValueGBX 2,630 per share Price / Book4.07Miscellaneous Outstanding Shares1,924,030,520Free FloatN/AMarket Cap£206.19 billion OptionableNot Optionable Beta0.17 20 Stocks to Sell NowGet This Free Report This page (LON:AZN) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredAI Boom Takes a Shocking Turn…What 99% of Investors are Missing in AI I believe it could be worth a fortune in the near future, yet hardl...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.